Cas:380487-65-0 alpha-Epoxydihydroartemisinic acid manufacturer & supplier

Chemical Name:alpha-Epoxydihydroartemisinic acid

CAS.NO:380487-65-0

Synonyms:(2R)-2-[(1aR,3aS,4R,7R,7aS,7bS)-1a,4-Dimethyldecahydronaphtho[1,2-b]oxiren-7-yl]propanoic acid;Naphth[1,2-b]oxirene-7-acetic acid, decahydro-α,1a,4-trimethyl-, (αR,1aR,3aS,4R,7R,7aS,7bS)-

Molecular Formula:C₁₅H₂₄O₃

Molecular Weight:252.349

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:377.1±15.0 °C at 760 mmHg

Density:1.1±0.1 g/cm3

Index of Refraction:1.509

PSA:49.83000

Exact Mass:252.172546

LogP:2.70

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (2R)-2-[(1aR,3aS,4R,7R,7aS,7bS)-1a,4-Dimethyldecahydronaphtho[1,2-b]oxiren-7-yl]propanoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Naphth[1,2-b]oxirene-7-acetic acid, decahydro-α,1a,4-trimethyl-, (αR,1aR,3aS,4R,7R,7aS,7bS)- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(2R)-2-[(1aR,3aS,4R,7R,7aS,7bS)-1a,4-Dimethyldecahydronaphtho[1,2-b]oxiren-7-yl]propanoic acid Use and application,Naphth[1,2-b]oxirene-7-acetic acid, decahydro-α,1a,4-trimethyl-, (αR,1aR,3aS,4R,7R,7aS,7bS)- technical grade,usp/ep/jp grade.

Related News: Russia, which shares a 2,600-mile border with China, reported its first two coronavirus cases on Friday. alpha-Epoxydihydroartemisinic acid manufacturer The complete chemical and pharmaceutical industry chain consists of basic chemical raw materials, pharmaceutical intermediates, chemical raw materials and chemical preparations. alpha-Epoxydihydroartemisinic acid supplier Financial toxicity (FT) is more prevalent among individuals with atherosclerotic cardiovascular disease (ASCVD) than individuals with cancer, according to a study published in the June 1 issue of JACC: CardioOncology. alpha-Epoxydihydroartemisinic acid vendor Financial toxicity (FT) is more prevalent among individuals with atherosclerotic cardiovascular disease (ASCVD) than individuals with cancer, according to a study published in the June 1 issue of JACC: CardioOncology. alpha-Epoxydihydroartemisinic acid factory AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment.